Search
Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity. … Hemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX.
Ajmaline
go.drugbank.com/drugs/DB01426ApprovedWithdrawnAn alkaloid found in the root of Rauwolfia serpentina, among other plant sources. … The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the Wolff–Parkinson–White syndrome and in well tolerated monomorphic ventricular tachycardias.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IaSodium bisulfite
go.drugbank.com/drugs/DB14015ApprovedWithdrawnSodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.
Mixtures: Nephramine Liq IVCategories: Compounds used in a research, industrial, or household settingLithium cation
go.drugbank.com/drugs/DB01356ApprovedInvestigationalWithdrawnThe active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several … They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression.
Synonyms: Lithium ion, Lithium, ionNuvaxovid
go.drugbank.com/drugs/DB15810ApprovedInvestigational[L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada. … a productive infection in humans.
AVR118
go.drugbank.com/drugs/DB04979InvestigationalAVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs (including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment … for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia (wasting) in
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigational[A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963] … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression
Finotonlimab
go.drugbank.com/drugs/DB18859InvestigationalFinotonlimab is under investigation in clinical trial NCT04560894 (SCT-I10A Plus SCT510 Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma).
Tenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigationalTenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil]. … [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271]
Categories: Antivirals used in combination for the treatment of HIV infections